OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
MTMH$1030.0056

Murni Sadar Tbk PT

Healthcare Facilities & ServicesVerified

The company's capital structure is characterized by a debt-to-equity ratio of 0.52, indicating a moderate level of leverage. Its liquidity position is assessed as medium, with a current ratio of 0.43, suggesting potential challenges in meeting short-term obligations. The company's valuation metrics, including a price-to-earnings ratio of 48.84 and a price-to-book ratio of 1.44, suggest that the market is valuing the company at a premium relative to its book value and earnings. In terms of profitability, the company's return on equity is 2.95%, and its return on assets is 1.65%, which are below the industry norms for healthcare facilities and services. The company's operating income margin is 8.35%, and its net income margin is 3.21%, which are also below the industry median. The company's geographic exposure is concentrated in Indonesia, with operations in Medan, Jakarta, Tangerang, and Bali. The revenue concentration in these regions is not disclosed, but the company's operations are subject to the economic and regulatory environment of Indonesia. The company's segments are not disclosed in detail, but the services offered include outpatient installation, laboratory, radiology, and endoscopy. The company's growth trajectory is expected to be modest, with the current fiscal year's outlook indicating a slight increase in revenue. The next fiscal year's outlook is also positive, with a projected increase in revenue. The company's capital expenditure is negative, indicating a reduction in investment in new facilities or equipment. The company's risk assessment indicates a medium level of liquidity risk and a low level of dilution risk. The key flags include a negative net cash position after subtracting total debt, which could affect the company's ability to fund operations and investments. The company's dilution potential is low, and no significant adjustments have been applied to the valuation metrics. Recent events related to the company include the latest financial snapshot, which provides an overview of the company's financial position as of the latest available data. The company's financial performance is subject to the economic conditions in Indonesia and the healthcare sector.

30-day price · MTMH-30.00 (-2.9%)
Low$915.00High$1100.00Close$995.00As of12 May, 00:00 UTC
Profile
CompanyMurni Sadar Tbk PT
TickerMTMH.JK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. PT Murni Sadar Tbk operates private hospitals in Indonesia, offering a range of health services including outpatient care, laboratory, radiology, and endoscopy services, with a total bed capacity of 1,061 units.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

The company's capital structure is characterized by a debt-to-equity ratio of 0.52, indicating a moderate level of leverage. Its liquidity position is assessed as medium, with a current ratio of 0.43, suggesting potential challenges in meeting short-term obligations. The company's valuation metrics, including a price-to-earnings ratio of 48.84 and a price-to-book ratio of 1.44, suggest that the market is valuing the company at a premium relative to its book value and earnings. In terms of profitability, the company's return on equity is 2.95%, and its return on assets is 1.65%, which are below the industry norms for healthcare facilities and services. The company's operating income margin is 8.35%, and its net income margin is 3.21%, which are also below the industry median. The company's geographic exposure is concentrated in Indonesia, with operations in Medan, Jakarta, Tangerang, and Bali. The revenue concentration in these regions is not disclosed, but the company's operations are subject to the economic and regulatory environment of Indonesia. The company's segments are not disclosed in detail, but the services offered include outpatient installation, laboratory, radiology, and endoscopy. The company's growth trajectory is expected to be modest, with the current fiscal year's outlook indicating a slight increase in revenue. The next fiscal year's outlook is also positive, with a projected increase in revenue. The company's capital expenditure is negative, indicating a reduction in investment in new facilities or equipment. The company's risk assessment indicates a medium level of liquidity risk and a low level of dilution risk. The key flags include a negative net cash position after subtracting total debt, which could affect the company's ability to fund operations and investments. The company's dilution potential is low, and no significant adjustments have been applied to the valuation metrics. Recent events related to the company include the latest financial snapshot, which provides an overview of the company's financial position as of the latest available data. The company's financial performance is subject to the economic conditions in Indonesia and the healthcare sector.
Key takeaways
  • The company's capital structure is moderately leveraged, with a debt-to-equity ratio of 0.52.
  • The company's profitability metrics, including return on equity and return on assets, are below industry norms.
  • The company's liquidity position is assessed as medium, with a current ratio of 0.43.
  • The company's growth trajectory is expected to be modest, with a projected increase in revenue for the next fiscal year.
  • The company's risk assessment indicates a medium level of liquidity risk and a low level of dilution risk.
  • # RATIONALES
  • margin_outlook_rationale: The company's operating and net income margins are below industry norms, indicating potential challenges in maintaining profitability.
  • rd_outlook_rationale: The company's research and development outlook is not disclosed, but the healthcare sector typically requires ongoing investment in new services and technologies.
Financial snapshot
PeriodHA-latest
CurrencyIDR
Revenue$1.36T
Gross profit$405.32B
Operating income$113.37B
Net income$43.62B
R&D
SG&A
D&A
SBC
Operating cash flow$257.47B
CapEx-$352.16B
Free cash flow-$136.58B
Total assets$2.65T
Total liabilities$1.17T
Total equity$1.48T
Cash & equivalents
Long-term debt$769.47B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$1030.00
Market cap$2.13T
Enterprise value$2.90T
P/E48.8
Reported non-GAAP P/E
EV/Revenue2.1
EV/Op income25.6
EV/OCF11.3
P/B1.4
P/Tangible book1.4
Tangible book$1.48T
Net cash-$769.47B
Current ratio0.4
Debt/Equity0.5
ROA1.7%
ROE2.9%
Cash conversion5.9%
CapEx/Revenue-25.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
MetricMTMHActivity
Op margin8.3%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin3.2%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin29.8%19.7% medp25 19.7% · p75 39.8%above median
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-25.9%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity52.0%71.3% medp25 19.0% · p75 91.7%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 12:40 UTC#9c3037a8
Market quoteclose IDR 1030.00 · shares 2.07B diluted
no public URL
2026-05-10 12:40 UTC#4a89b9e1
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 12:42 UTCJob: 67dffcbd